Luis Raez, MD

Articles by Luis Raez, MD

Selecting First-Line Therapy for EGFR-Mutated NSCLC

ByMisako Nagasaka, MD, PhD,Luis Raez, MD,Edgardo Santos, MD, FACP, FASCO,Jun Zhang, MD, PhD

October 31st 2025

Experts discuss applying emerging evidence from MARIPOSA and FLAURA2 to first-line decision-making in EGFR-mutated disease.

Patient Profile 1: Baseline Brain Metastases and Frontline Decision-Making

ByMisako Nagasaka, MD, PhD,Luis Raez, MD,Edgardo Santos, MD, FACP, FASCO,Jun Zhang, MD, PhD

October 31st 2025

Misako Nagasaka, MD, PhD, Dr. Nagasaka introduces the panel and outlines the session’s focus on applying new EGFR-mutated NSCLC data to practice, with emphasis on CNS control and toxicity prevention.

Luis Raez, MD

Articles by Luis Raez, MD

Selecting First-Line Therapy for EGFR-Mutated NSCLC

Patient Profile 1: Baseline Brain Metastases and Frontline Decision-Making

Latest Updated Articles

Trending on CancerNetwork

177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC

Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups